Industry News

Pharmaceutical Industry News

After Jenny Pearson’s daughter…

September 4th, 2026|Fierce Pharma|

After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. But a follow-up scan a year later, just days before

Daiichi Sankyo subsidiary American…

September 4th, 2026|Fierce Pharma|

Daiichi Sankyo subsidiary American Regent is launching a recall of three lots of generic epinephrine as it becomes one of the latest manufacturers to face headaches over particulate contamination in its drug products.

GSK, Roche and Novartis continued…

September 3rd, 2026|Fierce Pharma|

GSK, Roche and Novartis continued their dealmaking spree with Asian companies. Three midsized Asian biopharmas reached MFN deals with the White House. Akeso and Summit's ivonescimab delivered a head-to-head overall survival win against Keytruda. And

Following a string of customer…

September 3rd, 2026|Fierce Pharma|

Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah is contending with a warning letter from the FDA.

The social media collaboration…

September 3rd, 2026|Fierce Pharma|

The social media collaboration ties into Novartis' "you know your MS best" messaging, which encourages patients to keep track of changes in their disease.

Two votes of confidence from…

September 3rd, 2026|Fierce Pharma|

Two votes of confidence from leaders at the FDA’s Office of Clinical Evaluation and the Oncology Center of Excellence sealed Replimune’s fate, overruling review staffers’ concerns and paving the way for last month’s accelerated nod

About two years ago, a…

September 3rd, 2026|Fierce Pharma|

About two years ago, a head-to-head progression-free survival win made Akeso and Summit’s ivonescimab—and the PD-1xVEGF class—the most promising agent to replace Keytruda. Now, that same trial has met its overall survival endpoint, but to

The new business unit is centered…

September 2nd, 2026|Fierce Pharma|

The new business unit is centered on four core capabilities, which includes AI-enhanced scientific intelligence, omnichannel "scientific ecosystems," and more.

RNA-based vaccines and…

September 2nd, 2026|Fierce Pharma|

RNA-based vaccines and therapeutics may have faced a bumpy road in the U.S. recently, but a major new federal investment proves the government is still betting big on its future.

On the back of a heart-helping win…

September 2nd, 2026|Fierce Pharma|

On the back of a heart-helping win for the 11-year-old Repatha last fall, Amgen has continued to deepen the evidence on its PCSK9 inhibitor’s ability to cut cardiovascular risks in many patients.